FARAPULSE PFA System
Revenue Exposure
FARAPULSE launched in the U.S. in early 2024 and is now the predominant component of Electrophysiology revenue, driving consolidated sales growth of 19.9% in 2025.
Relevance 95·Dependency 85·Confidence 96
Source evidence
“led by the continued growth of our Farapulse™ Pulsed Field Ablation System which launched in the U.S. in early 2024”
Third-party payer reimbursement (Medicare/Medicaid, private plans, tenders)
Regulatory Exposure
Reimbursement approval is critical to product acceptance; changes in U.S., Japan, China reimbursement systems could materially adversely affect results.
Relevance 90·Dependency 85·Confidence 90
Source evidence
“legislative or administrative reforms to the reimbursement systems in the U.S., Japan, China, or other countries in a manner that significantly reduce or eliminate reimbursement for procedures using our medical devices”
Hospitals, physicians and health care providers
Customer Exposure
Products purchased principally by hospitals, physicians and other providers who bill third-party payers; consolidation of purchasing power and payer policies affect demand and pricing.
Relevance 90·Dependency 85·Confidence 90
Source evidence
“Our products are purchased principally by hospitals, physicians and other health care providers around the world”
Federal Food, Drug and Cosmetic Act (FDA)
Regulatory Exposure
US commercialization of products requires FDA clearance or approval under the FDC Act, which can be lengthy, costly and may limit indicated uses.
Relevance 88·Dependency 82·Confidence 94
Source evidence
“medical devices must receive FDA clearance or approval or an exemption from such clearance or approval before they can be commercially marketed in the U.S.”
EU Medical Device Regulation (MDR)
Regulatory Exposure
Boston Scientific's EU market access depends on MDR compliance and CE Marking, with extended transition periods to 2027/2028 for certain devices.
Relevance 85·Dependency 80·Confidence 94
Source evidence
“In the EU, we are required to comply with the Medical Device Regulation (MDR), which became effective in May 2021 and changed multiple aspects of the regulatory framework for CE Marking”
WATCHMAN LAAC Devices
Revenue Exposure
Continued market penetration of WATCHMAN LAAC procedures was a primary driver of 2025 Cardiovascular sales growth.
Relevance 80·Dependency 65·Confidence 90
Source evidence
“continued market penetration of Left Atrial Appendage Closure (LAAC) procedures with our WATCHMAN™ LAAC Devices”
Company anticipates incremental costs under the current schedule of U.S. tariffs on imports and potential China tariff increases on U.S.-made products.
Relevance 80·Dependency 60·Confidence 90
Source evidence
“We continue to anticipate incurring incremental costs under the current schedule of tariffs on U.S. imports announced by the U.S. government, as well as any potential increases in tariffs introduced by China on U.S. manufactured products.”
Third-party vendors / supply chain
Supplier Dependency
Economic conditions could reduce or interrupt supply of materials and components used in manufacturing products.
Relevance 75·Dependency 70·Confidence 85
Source evidence
“these conditions could also adversely affect our third-party vendors, including those that we utilize in our supply-chain and manufacturing operations, which may lead to a reduction or interruption in the supply of materials and components”
Inflation and macroeconomic conditions
Cost Driver
Inflation, interest rates, exchange rates, tariffs and geopolitical developments affect operational costs, customer spending and supplier/distributor health.
Relevance 75·Dependency 60·Confidence 85
Source evidence
“Continued inflationary pressure may also increase certain operational costs, including due to wage increases, or increases in the cost of materials or components.”
Health care cost containment and reimbursement policy
Demand Driver
Changes that lower reimbursements, reduce procedure volumes, or increase cost containment pressures could adversely affect demand and results.
Relevance 75·Dependency 60·Confidence 92
Source evidence
“any changes that lower reimbursements for either our products and/or procedures using our products reduce medical procedure volumes”
FDA and PMDA approvals
Regulatory Exposure
Revenue expansion depends on regulatory approvals; FDA (Q2 2025) and Japan PMDA (Q3 2025) label expansions for FARAPULSE, and FDA clearance distinctions like Intracept, drive product adoption; discontinuation decision on ACURATE followed regulatory pathway considerations.
Relevance 70·Dependency 60·Confidence 88
Source evidence
“We received FDA approval in the United States, and Pharmaceuticals and Medical Device Agency (PMDA) approval in Japan, in the second and third quarters of 2025, respectively, to expand instructions for use labeling to include the treatment of drug refractory, symptomatic persistent AF with the FARAPULSE™ PFA System.”
EU General Data Protection Regulation (GDPR)
Regulatory Exposure
GDPR imposes strict data-protection requirements and significant potential penalties affecting operations and data transfers.
Relevance 70·Dependency 60·Confidence 92
Source evidence
“In the European Union, the General Data Protection Regulation (GDPR) imposes strict requirements and significant potential penalties.”
Emerging Markets growth ($2,985M in 2025) was primarily driven by China; China tariffs on U.S.-manufactured products are also cited as a risk.
Relevance 70·Dependency 55·Confidence 88
Source evidence
“Reported net sales growth was primarily driven by growth in China, fueled by the breadth of our portfolio and focus on innovation and strong commercial execution.”
AI and digital technologies
Competitive Exposure
AI/ML are increasingly important to competitive environment and R&D; company believes new digital capabilities are needed to remain competitive.
Relevance 70·Dependency 55·Confidence 85
Source evidence
“We believe we will need to develop new and enhanced digital capabilities and competences in order to remain competitive.”
Economic slowdown / recession
Demand Driver
A general economic slowdown or recession may decrease customer spending and demand for products and impair customers' ability to pay.
Relevance 65·Dependency 55·Confidence 85
Source evidence
“If there were a general economic slowdown or recession, we may experience decreased customer spending or demand for our products and services”
Changing trade and tariff policies
Geopolitical Exposure
Forward-looking risk factors explicitly cite changing trade and tariff policies among conditions that could cause results to vary materially.
Relevance 65·Dependency 55·Confidence 80
Source evidence
“future U.S. and global political, competitive, reimbursement and regulatory conditions, including changing trade and tariff policies; geopolitical events and tensions”
Cybersecurity threat landscape (generative AI, quantum computing)
Customer Exposure
Evolving cyber-attacks using generative AI and quantum computing could disrupt operations, expose patient data, or harm patients.
Relevance 65·Dependency 50·Confidence 90
Source evidence
“generative AI and quantum computing, which are evolving rapidly in their practicality and use for cyber-attacks”
Continued increases in cost and limited availability of raw materials, components and inputs, plus wage and distribution cost increases amid global supply chain inflation.
Relevance 65·Dependency 50·Confidence 85
Source evidence
“we have continued to experience, and may in the future experience, increases in cost and limited availability of certain raw materials, components, and other inputs necessary to manufacture and distribute our products due to constraints and inflation within the global supply chain”
AGENT Drug-Coated Balloon
Revenue Exposure
Coronary therapies franchise led by AGENT Drug-Coated Balloon cited as a primary growth driver in 2025.
Relevance 65·Dependency 45·Confidence 85
Source evidence
“as well as our coronary therapies franchise led by our AGENT™ Drug-Coated Balloon”
Interest rates and credit market conditions
Revenue Exposure
Rate environment disrupts financial markets, affecting credit market access for M&A, supplier financing, and customer purchases especially of capital equipment.
Relevance 60·Dependency 50·Confidence 80
Source evidence
“These conditions could affect our ability to access credit markets, including to obtain financing for mergers and acquisitions (M&A) or for other general purposes.”
Climate change and extreme weather
Cost Driver
Climate change and natural disasters could disrupt supply chain, manufacturing, raw materials, and energy supply, and increase compliance costs.
Relevance 60·Dependency 45·Confidence 90
Source evidence
“could adversely impact our supply chain, including manufacturing and distribution networks, the availability and cost of raw materials and components, energy supply, transportation”
Skilled labor shortage
Cost Driver
A shortage of skilled labor could require higher wages and increase labor costs; competition for key personnel is substantial.
Relevance 55·Dependency 45·Confidence 90
Source evidence
“A shortage of skilled labor could also require higher wages that would increase labor costs.”
China Personal Information Protection Law (PIPL)
Regulatory Exposure
PIPL and related Chinese regulations impose data-localization and government-approval requirements affecting data handling in China.
Relevance 55·Dependency 40·Confidence 90
Source evidence
“China’s data‑protection and cross‑border transfer laws, including requirements under the Personal Information Protection Law (PIPL)”
foreign currency fluctuations
Revenue Exposure
FX fluctuations reduced 2025 reported growth by 0.7 percentage points; operational (constant currency) growth was 19.2% vs 19.9% reported.
Relevance 55·Dependency 40·Confidence 85
Source evidence
“Impact of foreign currency fluctuations(0.7)%0.9 % Net sales operational growth (non-GAAP measure) 19.2 %18.5 %”